Future Directions for CDK4/6 Inhibitors and the Expanding Role of Pharmacists in Breast Cancer Care

In the final episode, Future Directions for CDK4/6 Inhibitors and the Expanding Role of Pharmacists in Breast Cancer Care, the panelists explored the following critical questions:

Which additional clinical trials would you like to see with CDK4/6 inhibitors in the future?

How do you envision the role of CDK4/6 inhibitors evolving in the next 5 years?

Overall, how do you envision the role of the pharmacist evolving in caring for patients with early and metastatic breast cancer in the next 5 years?

Led by the moderator, the experts examined several areas where additional clinical trials with CDK4/6 inhibitors could further refine their role in breast cancer care. Future research may explore optimal sequencing strategies, combination regimens with emerging targeted therapies, and biomarkers that can better predict which patients will benefit most from treatment with agents such as palbociclib, ribociclib, and abemaciclib. Additional studies may also evaluate the duration of therapy and investigate their role in earlier disease settings or in patients with specific high-risk features. Over the next five years, the use of CDK4/6 inhibitors is expected to continue expanding as long-term data mature and as clinicians gain greater clarity on patient selection and treatment sequencing. Advances in precision medicine and biomarker-driven strategies may further help tailor therapy and improve outcomes. At the same time, the role of pharmacists in managing patients with early and metastatic breast cancer is lik

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this Pharmacy Times Peer Exchange series on breast cancer. Please subscribe to our newsletter for information on upcoming video series.